EP3181229B1 - Procédé pour l'execution d'une reaction pcr - Google Patents

Procédé pour l'execution d'une reaction pcr Download PDF

Info

Publication number
EP3181229B1
EP3181229B1 EP15003599.6A EP15003599A EP3181229B1 EP 3181229 B1 EP3181229 B1 EP 3181229B1 EP 15003599 A EP15003599 A EP 15003599A EP 3181229 B1 EP3181229 B1 EP 3181229B1
Authority
EP
European Patent Office
Prior art keywords
chamber
chambers
amplification
annealing
liquid sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15003599.6A
Other languages
German (de)
English (en)
Other versions
EP3181229A1 (fr
Inventor
Markus Cavalar
Ulf Steller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euroimmun Medizinische Labordiagnostika AG
Original Assignee
Euroimmun Medizinische Labordiagnostika AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euroimmun Medizinische Labordiagnostika AG filed Critical Euroimmun Medizinische Labordiagnostika AG
Priority to EP15003599.6A priority Critical patent/EP3181229B1/fr
Priority to DE102016013403.8A priority patent/DE102016013403A1/de
Publication of EP3181229A1 publication Critical patent/EP3181229A1/fr
Application granted granted Critical
Publication of EP3181229B1 publication Critical patent/EP3181229B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L7/00—Heating or cooling apparatus; Heat insulating devices
    • B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
    • B01L7/525—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples with physical movement of samples between temperature zones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0621—Control of the sequence of chambers filled or emptied
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/087—Multiple sequential chambers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/088—Channel loops

Definitions

  • PCR polymerase chain reaction
  • pathogens viruses, bacteria, fungi, parasites
  • MRSA methicillin-resistant Staphylococcus aureus
  • certain human nucleic acid sequences that are of diagnostic importance, for example because they have mutations associated with certain diseases, can be detected in patient samples.
  • PCR is also important outside of medical applications, for example when examining soil or food samples for certain microorganisms, in forensics or in the synthetic production of complex nucleic acids.
  • PCR requires considerable effort with regard to reagents, equipment and workload, especially in diagnostic applications.
  • a reaction batch has to be put together that contains a whole series of specific, partly thermo-unstable reagents.
  • the finished reaction batch has to be incubated cyclically at different temperatures for a long time. A single error or inactivation of a reagent prevents the reaction from proceeding.
  • reaction must be protected against contaminations through which the nucleic acids falsifying the result can be introduced, as well as against substances that can accelerate the decay of essential reagents.
  • reaction product requires considerable equipment, for example a device that allows sensitive fluorescence measurements.
  • Samples to be analyzed must then be packaged and sent to a special laboratory where a large number of samples are processed. This delays the analysis and increases the costs. During transport, there is a risk that a sample will be lost, spoiled or become unusable due to damage.
  • EP 1769848 A2 discloses a chemical reaction cartridge comprising three or more chambers.
  • DE 102014200509 A1 discloses an analysis unit for performing a PCR, the analysis unit comprising three or more chambers.
  • an object on which the present invention is based is to provide a system for the implementation of PCR reactions which is as user-friendly as possible and which is easy to use and in particular does not require the preparation of complex reaction batches.
  • the system should function as quickly as possible and save resources (time, energy, reagent and sample consumption), demand no special conditions and be as little susceptible to faults, damage and operating errors as possible.
  • the system should allow the parallel processing of as many samples as possible.
  • the system should enable the analysis of any type of sample or any interesting analysis with the largest possible spectrum of parameters, flexibly and at short notice. It should be possible to examine a sample, for example from a patient, for several diagnostic parameters with as little effort and time as possible.
  • the system should combine the advantages mentioned with protection against external contamination, which could be entered, for example, by the personnel entrusted with the operation.
  • the device further comprises an analytical reagent which is soluble in the liquid sample, preferably a lyophilized reagent.
  • a mixing chamber is provided downstream of the receiving chamber and upstream of the denaturing chamber, preferably directly upstream, which preferably has the analytical reagent.
  • the analytical device comprises at least two sets of chambers, each comprising a denaturing chamber, an amplification chamber and an annealing chamber, whereby preferably a mixing chamber is provided downstream of the receiving chamber and upstream of the denaturing chamber, particularly preferably directly upstream, which preferably contains the analytical reagent and a part of a liquid sample can be transferred from the mixing chamber into a chamber of the respective set.
  • the diagnostic device has at least one heating zone, the denaturing chamber, preferably additionally the amplification chambers, more preferably additionally the annealing chambers of the at least two sets each being arranged on a heating zone.
  • the device has a readout chamber into which the liquid sample from the denaturing chamber, from the amplification chamber or from the annealing chamber can be transferred.
  • the readout chamber comprises at least one immobilized nucleic acid.
  • the diagnostic device is a laboratory chip.
  • an analysis unit suitable for receiving the analytical device preferably comprising the analytical device, is disclosed herein. comprising a heating device which is designed such that the required temperature can be set in the denaturing chamber, amplification chamber and annealing chamber and / or in the heating zone for the denaturing chambers, amplification chamber and annealing chambers and / or comprising means for reading a liquid sample in the reading chamber of the analytical device.
  • the device comprises a nucleic acid-containing liquid sample.
  • the present invention relates to a method comprising an analytical device with at least one set of chambers, each comprising a denaturing chamber, an amplification chamber and an annealing chamber.
  • the analytical device allows an externally obtained sample to be introduced into the denaturing chamber, optionally via another chamber.
  • the sample is a liquid sample or a solid sample, provided the latter is taken up in a liquid inside the analytical device, so that the sample is also available in liquid form for further processing.
  • a suitable device for transferring a solid sample into a liquid and a method is, for example, in US Pat EP15002317.4 described.
  • the sample is preferably a sample containing nucleic acid or a sample which is to be examined for whether it contains a nucleic acid, wherein the sample can be in a largely unprocessed form, for example a sample obtained directly from a patient or a soil sample.
  • the sample can be prepared, for example by isolating and / or enriching the nucleic acid contained therein.
  • the nucleic acid can be any nucleic acid or a derivative thereof that can be amplified using a polymerase chain reaction (PCR), preferably DNA or RNA.
  • the device comprises a system with chambers and connecting channels that can be locked, preferably closed, from the environment.
  • “lockable” means that the inner system can be opened temporarily for the introduction of a sample; in the closed state, it is not possible to introduce the sample or contaminating material.
  • the system can have an opening that can be closed with a lid.
  • a liquid sample controlled by the user or a control unit, can be moved in a compact, coherent form, in particular by transfer from a first chamber to a second chamber.
  • the connecting channels can include valves that allow the control of a liquid flow. The isolation from the environment prevents external contamination and loss of liquid through evaporation.
  • the term "chamber" as used herein means an area within the device in which the entire liquid sample can be incubated in a compact, coherent form under essentially defined, uniform conditions.
  • a chamber can be a cavity which is geometrically delimited by its shape, for example has a widened diameter and a correspondingly larger volume compared to a connecting channel.
  • a chamber can be created in such a way that the liquid sample continuously occupies a delimited area of a connecting channel, the surface of the liquid forming the boundary of the chamber relative to the gas phase surrounding it.
  • the chambers can be designed to be lockable to prevent liquid sample from escaping, for example from a chamber at high temperature.
  • laboratory chip as used herein is understood to mean a closed system which contains chambers and connecting channels in which all steps from the introduction of an unprocessed sample through its preparation and processing to analysis can be carried out ,
  • the device has at least one set comprising a denaturing chamber, an amplification chamber and an annealing chamber, for example 2, 3, 4, 5, 6, 8 or 12 sets.
  • the denaturing chamber is designed and has suitable conditions such that a double-stranded nucleic acid contained in the liquid sample can be denatured, ie the double strands dissolve with the release of corresponding single strands.
  • the temperature can be set to a suitable value or is set to it, preferably between 90 ° C. and 105 ° C., more preferably between 90 ° C. and 99 ° C.
  • suitable conditions in particular to determine a suitable temperature for denaturing a given double-stranded nucleic acid.
  • the annealing chamber is designed and has suitable conditions such that primers contained in the liquid sample specifically anneal to the single strands of the nucleic acid in the liquid sample, i.e. hybridize specifically with them.
  • the temperature can be set to a suitable value or is set to it, preferably between 40 ° C and 67 ° C.
  • suitable conditions in particular a suitable temperature, for the annealing of given primers to the single strands of a given nucleic acid with sufficient specificity.
  • the amplification chamber is designed and has suitable conditions such that the single strands of the nucleic acid are synthesized from the annealed primers into a double strand by a polymerase present. As a result, the part of a double-stranded nucleic acid delimited by the primers becomes the liquid introduced into the device Sample amplified.
  • the person skilled in the art is able to determine suitable conditions as part of routine calculations and preliminary tests.
  • the temperature can be set to a suitable value or is set to it, preferably between 60 ° C and 80 ° C, more preferably between 65 ° C and 74 ° C.
  • the amplification chamber is connected downstream of the denaturation chamber.
  • the term means that a second chamber is "downstream" of a first, as used herein, that a liquid sample introduced into the device, which passes through the device in the shortest possible way, first passes the first chamber and then the second Chamber.
  • the fact that a second chamber is “directly downstream” of a first means that the sample is transferred from the first chamber directly into the second chamber without passing through further chambers in between.
  • the device to which at least one set comprising a denaturing chamber, an amplification chamber and an annealing chamber is connected upstream, preferably directly upstream, has a mixing chamber.
  • the mixing chamber is designed such that a volume of the liquid sample suitable for the detection reaction can be transferred therefrom into the at least one set. If the device has more than one set, the mixing chamber allows the liquid sample to be portioned in a suitable manner, so that a part in each set the liquid sample is transferred with a volume sufficient for the detection reaction.
  • the device preferably further comprises an analytical reagent.
  • the analytical reagent comprises all substances which are necessary for carrying out the detection reaction, preferably the PCR reaction, provided that these are not already present in the liquid sample or their presence in the liquid sample is to be detected.
  • the liquid sample comprises the nucleic acid to be amplified or is to be examined for whether it contains the nucleic acid to be amplified
  • the analytical reagent comprises, in addition to a nucleic acid suitable as a template, all other substances which are necessary for carrying out the PCR reaction.
  • the analytical reagent is preferably in a dry, preferably lyophilized, form. It is such that it dissolves in contact with the liquid sample so that the substances required for the detection reaction, preferably the PCR reaction, are present in sufficient concentration.
  • the device optionally has a means or a suitable method step is provided to promote the dissolution of the analytical reagent in the sample. For example, the liquid sample can be contacted several times with the reagent, or the analytical reagent is mixed with the liquid sample by a micro stirrer.
  • the analytical reagent preferably comprises a polymerase and / or reverse transcriptase, dNTPs, a buffer, magnesium chloride, at least one primer, preferably at least one pair of primers, optionally labeled, a detergent, preferably from the group comprising betaine, tween or dimethyl sulfoxide, and a polypeptide such as bovine serum albumin.
  • the analytical reagent comprises several substances, these can be located separately from one another in the device.
  • the analytical reagent is preferably in a compact form which comprises all substances.
  • the analytical reagent can be located in any part of the device, provided that it is ensured that it comes into contact with the liquid sample and is mixed before the detection reaction is carried out. It is preferably located in the mixing chamber.
  • each set of chambers can contain at least one specific reagent, in particular one or more than one primer, which dissolves in the part of the liquid sample which is transferred into this set.
  • the device has more than one set of chambers, it preferably comprises at least one heating zone.
  • This is a device for continuous heating of an area on the device in which at least two chambers are located, which are preferably set to the same temperature. If the device comprises two sets, for example, then both denaturing chambers can be set to a temperature of 95 ° C. with the same heating zone.
  • the temperature of all denaturing chambers can be set by a heating zone for the denaturing chambers or is set for them, so that the same temperature prevails in the denaturing chambers.
  • the temperature of all amplification chambers can be set by a heating zone for the amplification chambers or is set for them, so that the same temperature prevails in the amplification chambers.
  • the temperatures of the respective annealing chambers can be set individually.
  • the temperature of all annealing chambers can be set by a heating zone for the annealing chambers or is set for them, so that the same temperature prevails in the annealing chambers.
  • the temperature of all denaturation chambers and all amplification chambers can be set or is set for them by a heating zone for all denaturation chambers or by a heating zone for all amplification chambers, so that the same temperature prevails in all denaturation chambers and so that in all Amplification chambers have the same temperature.
  • the temperatures of the respective annealing chambers and / or denaturing chambers can be set individually.
  • the temperature of all denaturing chambers, all amplification chambers and all annealing chambers can be set or is set for them by a heating zone for all denaturing chambers or by a heating zone for all amplification chambers or by a heating zone for all annealing chambers all denaturation chambers have the same temperature, all amplification chambers have the same temperature and all annealing chambers have the same temperature.
  • the analytical device is a disposable item which is discarded in its entirety after use.
  • the disposable article is adapted to an analysis unit to be used several times, each with a new disposable article, in such a way that the latter has at least one heating device with which the required denaturation chamber, amplification chamber and annealing chamber and / or in the heating zone for the denaturation chambers, amplification chamber and annealing chambers Temperature can be set or is set.
  • the analysis unit preferably contains a means for reading out a liquid sample, which is located in the reading chamber of the analytical device, which in turn has been introduced into the analysis unit.
  • This can be a fluorescence spectroscope if the amplified nucleic acid contains a fluorescence label or a UV / vis spectrophotometer if it contains a chromophore.
  • the analysis unit can also include further units, for example for the internal transport of disposable articles introduced into the analysis unit and for processing data which are obtained when analyzing a liquid sample in a disposable article.
  • the method according to the invention is preferably a method for the detection of a nucleic acid sequence, more preferably a diagnostic method for the detection of a nucleic acid sequence.
  • the nucleic acid sequence can be a human sequence or the sequence of a pathogen.
  • the method requires the introduction of a liquid sample into the device.
  • the sample is first introduced into the open receiving chamber. If it is a non-liquid sample, it can first be transferred to a liquid phase. There is also the possibility of having the sample already in the Mixing chamber or previously with analytical reagent. The access of the receiving chamber to the surface of the device can then be closed.
  • the liquid sample is then transferred to the denaturing chamber; optionally, it can be contacted with analytical reagent beforehand in a mixing chamber and / or portioned into chambers for transfer to several sets.
  • the denaturation is carried out in the denaturation chamber (step a).
  • the liquid sample from step a) is then transferred into the annealing chamber, and the annealing is carried out therein (step b).
  • the liquid sample from step b) is then transferred into the amplification chamber, and the amplification is carried out (step c).
  • reaction cycle comprising steps a), b), and c) is repeated at least 10 times. In total, at least 15, 20, 30, 40 or 45 reaction cycles are preferably carried out.
  • the liquid sample preferably from step c) carried out last, is transferred to the readout chamber and read out there. After reading, it can be discarded by transferring it to the waste chamber. If at least two detection reactions are carried out in at least two sets of chambers, these are preferably carried out simultaneously or at least overlapping in order to minimize the overall duration of the method. The parts of the liquid sample from these at least two detection reactions are then successively transferred to the read-out chamber and read out there and then discarded by transfer to the waste chamber, at least all parts of the liquid sample except for the last part that can remain in the read-out chamber.
  • the device contains two or more readout chambers.
  • Parts of the liquid sample from different sets can each be analyzed comprising a denaturing chamber (5), an amplification chamber (6) and an annealing chamber (7) in different readout chambers, for example with microarrays that differ in the probes and / or primers they contain , Alternatively, a sample or part of a sample can be analyzed in different readout chambers.
  • Fig. 1 shows a preferred embodiment of the analytical device (1).
  • This has a receiving chamber (2) which can be closed with a cover (13) and into which a sample can be introduced.
  • the sample can be transferred in liquid form into a mixing chamber (3) from the receiving chamber.
  • the analytical reagent When it arrives in the mixing chamber, it comes into contact with an analytical reagent (4), which dissolves in the liquid sample.
  • the analytical reagent preferably has all the reagents required for a PCR reaction, except for the nucleic acid to be amplified, so that - provided that the sample contains the nucleic acid - all the reagents required for the reaction are present after dissolution.
  • the liquid sample can then be divided, and in each case a part enters a denaturing chamber (5), which is part of a set comprising a denaturing chamber (5), an amplification chamber (6) and an annealing chamber (7).
  • All denaturing chambers are arranged in a heating zone for the denaturing chambers (8), analogously all amplification chambers and all annealing chambers in the heating zone for the amplification chambers (9) and heating zone for the annealing chambers (10).
  • the different sets can contain specific reagents for different detection reactions.
  • a first set can contain a first pair of primers and a second set can contain another second pair of primers.
  • Non-specific reagents required for all reactions can be added to the sample beforehand, for example in the mixing chamber (3).
  • a PCR reaction can be carried out in such a way that the liquid sample is first introduced into the denaturation chamber under suitable conditions, is present there and double strands of nucleic acid dissolve and single strands are released.
  • the sample is then transferred to the annealing chamber, comprising the individual strands, and is present there under conditions which allow the primers to be annealed to the single strands.
  • the liquid sample with single strands and primers attached to them is then transferred into the amplification chamber and is present there under conditions which, starting from the primers, permit the amplification, ie the synthesis of new single strands which are complementary to the existing single strands.
  • the sample can then be transferred to the denaturation chamber again for the start of a new amplification cycle comprising steps a), b) and c).
  • the part of the sample which was contained in one of the sets comprising a denaturing chamber (5), an amplification chamber (6) and an annealing chamber (7) can be transferred to the readout chamber (11).
  • a suitable detection reaction takes place there, for example a fluorescence measurement, with which nucleic acid strands can be detected which contain at least one fluorescence-labeled primer and in this way differ from nucleic acids which were already contained in the sample originally introduced into the device.
  • the part of the sample contained in the readout chamber can be discarded by transferring it to the waste chamber (12).
  • the readout chamber is thus empty and is ready for a part of the sample from another set to be transferred to it and to be examined with a detection reaction. In this way, several parts of the liquid sample can be examined in the same readout chamber.
  • Fig. 2 shows a further preferred embodiment of the analytical device (1). It differs from that in Fig. 1 demonstrated device in particular in that it contains an annular channel in which the denaturing chamber, amplification chamber and annealing chamber are not provided in the form of geometrically delimited chambers, but in that the liquid sample (14) in the form of a compact, coherent drop along the ring is transferred into the heating zone of the denaturing chamber, amplification chamber or annealing chamber (8, 9 or 10). Together with the walls of the annular channel, the boundary surfaces of this drop form the boundaries of the chamber, for example the denaturing chamber (5), as shown here.
  • a plurality of annular channels can be arranged one above the other perpendicular to the paper plane; the heating zones then preferably also run perpendicular to the plane of the paper, so that in each case one of the heating zones can heat or heats a plurality of ring-shaped channels at the corresponding point to the temperature desired for the denaturing chamber, amplification chamber or annealing chamber.
  • the liquid sample never leaves the annular channel during the PCR reaction. It is transmitted to the point of the ring-shaped channel that is currently required, at that point for the step to be carried out a), b) or c) there is a suitable temperature. In this way, there is no need to go through a bottleneck, ie a particularly narrow point, and the speed of the sample transfer between the different chambers can be maximized.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (10)

  1. Procédé comprenant
    un dispositif analytique (1) comprenant une chambre de dénaturation (5), une chambre d'amplification (6) et une chambre de recuit (7),
    dans lequel la température de la chambre de dénaturation (5) est réglée à une température comprise entre 90°C et 105°C,
    dans lequel la température de la chambre d'amplification (6) est réglée à une température comprise entre 60°C et 80°C,
    dans lequel la température de la chambre de recuit (7) est réglée à une température comprise entre 40°C et 67°C,
    et dans lequel le dispositif (1) est conçu de manière à ce qu'un échantillon liquide (14) puisse être introduit dans la chambre de dénaturation (5) et transféré par va-et-vient entre la chambre de dénaturation (5), la chambre d'amplification (6), la chambre de recuit (7) et éventuellement d'autres chambres (11, 12),
    caractérisé en ce que le dispositif analytique (1) comprend en outre une chambre de réception (2) comportant un accès à la surface du dispositif de diagnostic, par l'intermédiaire duquel l'échantillon (14) peut être introduit dans la chambre de réception (2) et ensuite transféré dans d'autres chambres (5, 6, 7),
    dans lequel la chambre d'amplification (6) est reliée en aval de la chambre de dénaturation (5) et la chambre de recuit (7) est reliée en aval de la chambre d'amplification (6),
    dans lequel le procédé comprend les étapes consistant à:
    a) introduire l'échantillon liquide (14) dans la chambre de dénaturation (5) du dispositif analytique (1), puis dénaturer l'échantillon,
    b) transférer l'échantillon liquide (14) provenant de l'étape a) dans la chambre de recuit (7), puis effectuer le recuit,
    c) transférer l'échantillon liquide provenant de l'étape b) dans la chambre d'amplification (6), puis effectuer l'amplification,
    d) répéter les étapes a), b) et c),
    e) transférer l'échantillon liquide (14) provenant de d) dans deux chambres de lecture (11) ou plus, puis lire l'échantillon liquide (14),
    dans lequel le cycle de réaction comprenant les étapes a), b) et c) est répété au moins 10 fois,
    dans lequel le dispositif analytique (1) comprend au moins deux ensembles de chambres comprenant chacune une chambre de dénaturation (5), une chambre d'amplification (6) et une chambre de recuit (7), et
    les deux chambres de lecture ou plus diffèrent par les sondes qu'elles contiennent.
  2. Procédé selon la revendication 1, dans lequel la chambre d'amplification (6) est reliée directement en aval de la chambre de dénaturation (5) et la chambre de recuit (7) est reliée directement en aval de la chambre d'amplification (6).
  3. Procédé selon l'une des revendications 1 ou 2 comprenant en outre un réactif analytique (4) qui est soluble dans l'échantillon liquide (14), de préférence un réactif lyophilisé.
  4. Procédé selon l'une des revendications 1 à 3, dans lequel il est prévu en aval de la chambre de réception (2) et en amont, de préférence directement en amont, de la chambre de dénaturation (5), une chambre de mélange (3) qui comporte de préférence le réactif analytique (4).
  5. Procédé selon l'une des revendications 1 à 4, dans lequel le dispositif de diagnostic (1) comprend au moins deux ensembles de chambres comprenant respectivement une chambre de dénaturation (5), une chambre d'amplification (6) et une chambre de recuit (7), et dans lequel il est prévu, de préférence en aval de la chambre de réception (2) et en amont, de préférence directement en amont, de la chambre de dénaturation (5), une chambre de mélange (3) qui comporte de préférence le réactif analytique (4), et une partie d'un échantillon liquide (14) peut être transférée de chaque chambre de mélange (3) vers une chambre (5, 6, 7) de l'ensemble respectif.
  6. Procédé selon la revendication 5, dans lequel le dispositif analytique (1) comporte au moins une zone de chauffage (8, 9, 10), dans lequel la chambre de dénaturation (5), de préférence également les chambres d'amplification (6), et également plus préférablement les chambres de recuit (7) desdits au moins deux ensembles sont respectivement disposées sur une zone de chauffage.
  7. Procédé selon l'une des revendications 1 à 6, dans lequel le dispositif (1) comporte la chambre de lecture (11) dans laquelle l'échantillon liquide (14) provenant de la chambre de dénaturation (5), de la chambre d'amplification (6) ou de la chambre de recuit (7) peut être transféré.
  8. Procédé selon l'une des revendications 1 à 7, dans lequel la chambre de lecture (11) comprend au moins un acide nucléique immobilisé.
  9. Procédé selon l'une des revendications 1 à 8, dans lequel le dispositif de diagnostic (1) est une puce de laboratoire.
  10. Procédé selon l'une des revendications 1 à 9, comprenant un échantillon liquide contenant un acide nucléique.
EP15003599.6A 2015-12-17 2015-12-17 Procédé pour l'execution d'une reaction pcr Active EP3181229B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP15003599.6A EP3181229B1 (fr) 2015-12-17 2015-12-17 Procédé pour l'execution d'une reaction pcr
DE102016013403.8A DE102016013403A1 (de) 2015-12-17 2016-11-11 Analytische Vorrichtung zur Durchführung einer PCR-Reaktion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15003599.6A EP3181229B1 (fr) 2015-12-17 2015-12-17 Procédé pour l'execution d'une reaction pcr

Publications (2)

Publication Number Publication Date
EP3181229A1 EP3181229A1 (fr) 2017-06-21
EP3181229B1 true EP3181229B1 (fr) 2020-02-26

Family

ID=55129374

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15003599.6A Active EP3181229B1 (fr) 2015-12-17 2015-12-17 Procédé pour l'execution d'une reaction pcr

Country Status (2)

Country Link
EP (1) EP3181229B1 (fr)
DE (1) DE102016013403A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384022A4 (fr) * 2001-04-06 2004-08-04 California Inst Of Techn Amplification d'acide nucleique au moyen de dispositifs microfluidiques
JP4830432B2 (ja) * 2005-09-30 2011-12-07 横河電機株式会社 化学反応用カートリッジおよびその使用方法
US9364833B2 (en) * 2012-08-17 2016-06-14 Lexmark International, Inc. Micro-fluidic modules on a chip for diagnostic applications
DE102014200509A1 (de) * 2014-01-14 2015-07-16 Robert Bosch Gmbh Analyseeinheit zum Durchführen einer verschachtelten Polymerasekettenreaktion, Analysevorrichtung, Verfahren zum Betreiben einer solchen Analyseeinheit und Verfahren zum Herstellen einer solchen Analyseeinheit
EP3127613B1 (fr) 2015-08-04 2019-07-24 Euroimmun Medizinische Labordiagnostika AG Dispositif de controle de materiau d'essai dans un liquide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
DE102016013403A1 (de) 2017-06-22
EP3181229A1 (fr) 2017-06-21

Similar Documents

Publication Publication Date Title
EP1740721B1 (fr) Procede et dispositif d'amplification d'adn par amplification en chaine par polymerase au moyen de reactifs secs
EP0581953B1 (fr) PROCEDE DE DETERMINATION D'ACIDES NUCLEIQUES AMPLIFIES $i(IN VITRO)
EP1192007B1 (fr) Dispositif matrice a microcircuit integre destine a l'amplification et a la caracterisation d'acides nucleiques
DE69918160T2 (de) Dreh-thermocyclervorrichtung
EP2926905A1 (fr) Dispositif microfluidique et procédé d'analyse d'un échantillon de matériau biologique
DE112012002801B4 (de) Genetisches Testsystem
WO2015158818A1 (fr) Module microfluidique et cartouche de diagnostic immunologique et moléculaire dans un analyseur automatique
DE60035977T2 (de) MIT FTA BESCHICHTETER TRäGER ZUR VERWENDUNG ALS MOLEKULARES DIAGNOSEMITTEL
EP1573051A1 (fr) Procede et dispositif pour determiner des germes
EP3181229B1 (fr) Procédé pour l'execution d'une reaction pcr
Kriegsmann et al. Applications of molecular pathology in the diagnosis of joint infections
DE102005054206B4 (de) Verfahren und Vorrichtung zum automatisierten Bearbeiten von gepoolten Proben
DE102014205728B3 (de) Chiplabor-Kartusche für ein mikrofluidisches System zum Analysieren einer Probe biologischen Materials, mikrofluidisches System zum Analysieren einer Probe biologischen Materials sowie Verfahren und Vorrichtung zum Analysieren einer Probe biologischen Materials
DE102014116204B3 (de) Verfahren zum quantitativen Nachweis einer Kontamination einer Flüssigkeit durch einen Mikroorganismus mittels quantitativer Polymerasekettenreaktion
DE212021000370U1 (de) Robotermechanismuseinheit zur Verwendung bei in vitro Diagnosetests und -analysen
DE102014200467A1 (de) Mikrofluidisches System sowie Verfahren zum Analysieren einer Probe biologischen Materials
DE102012014922A1 (de) Prüf- und Ergebnisfreigabeverfahren für diagnostische Systeme
DE102012014981B3 (de) Verfahren zur Differenzierung zwischen lebenden und toten Zellen
WO2021122979A1 (fr) Procédé et dispositif pour déterminer le nombre de copies d'une séquence d'adn présentes dans un fluide
AT18180U1 (de) Vorrichtung zur Aufnahme von Proben
EP3034619B1 (fr) Oligonucléotide modifié et procédé d'éclusage de primaires ou de molécules de commande ou de sondes dans des systèmes PCR fermés
WO2020127604A1 (fr) Procédé in vitro pour mettre en évidence au moins un acide nucléique présent chez un être vivant dans le sang total en dehors des cellules sanguines et dispositif et kit correspondants
WO1999025867A1 (fr) Procede permettant de detecter des acides nucleiques dans plusieurs echantillons
EP0994193A1 (fr) Procédé pour détecter des organismes basé sur leur acide nucléique
DE202022100905U1 (de) Vorrichtung zur Aufnahme von Proben

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171218

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180405

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190730

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CAVALAR, MARKUS

Inventor name: STELLER, ULF

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1236980

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502015011821

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200526

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200226

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200526

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200626

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200527

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200719

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502015011821

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

26N No opposition filed

Effective date: 20201127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201217

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 1236980

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230605

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231220

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231219

Year of fee payment: 9

Ref country code: DE

Payment date: 20231214

Year of fee payment: 9